A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL
PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
80
Participants
Timeline
Start Date
June 30, 2025
Primary Completion Date
August 31, 2025
Study Completion Date
February 28, 2027
Conditions
Relapsed/Refractory Indolent NHL
Interventions
DRUG
Linperlisib ； Rituximab
Linperlisib ； Rituximab
All Listed Sponsors
lead
Jiangsu HengRui Medicine Co., Ltd.
INDUSTRY
NCT06981988 - A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL | Biotech Hunter | Biotech Hunter